CRP and cancer: The authors report significantly improved progression-free (38.6 vs. 26.5-months) and cancer-specific (95.6% vs. 84.2%) survival, as well as latency to castrate-resistance (40 vs. 29-months) for men treated with CRP or ADT, respectively.